Cargando…

Preclinical Study of a Biodegradable Polymer-based Stent with Abluminal Sirolimus Release

BACKGROUND: Bioabsorbable polymer stents with drug elution only on the abluminal surface may be safer than durable polymer drug-eluting stents. OBJECTIVE: To report the experimental findings with the Inspiron(TM) stent - a bioabsorbable polymer-coated stent with sirolimus release from the abluminal...

Descripción completa

Detalles Bibliográficos
Autores principales: Takimura, Celso Kiyochi, Campos, Carlos Augusto Homem M., Melo, Pedro Henrique Magualhães Craveiro, Campos, Julliana Carvalho, Gutierrez, Paulo Sampaio, Borges, Thiago Francisco Costa, Curado, Luciano, Morato, Spero Penha, Laurindo, Francisco Rafael Martins, Lemos, Pedro Alves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Cardiologia 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051445/
https://www.ncbi.nlm.nih.gov/pubmed/24759951
http://dx.doi.org/10.5935/abc.20140044
Descripción
Sumario:BACKGROUND: Bioabsorbable polymer stents with drug elution only on the abluminal surface may be safer than durable polymer drug-eluting stents. OBJECTIVE: To report the experimental findings with the Inspiron(TM) stent - a bioabsorbable polymer-coated stent with sirolimus release from the abluminal surface only, recently approved for clinical use. METHODS: 45 stents were implanted in the coronary arteries of 15 pigs. On day 28 after implantation, angiographic, intracoronary ultrasonographic and histomorphological data were collected. Five groups were analyzed: Group I (nine bare-metal stents); Group II (nine coated with bioabsorbable polymer on the luminal and abluminal surfaces); Group III (eight stents coated with bioabsorbable polymer on the abluminal surface); Group IV (nine stents with bioabsorbable polymer and sirolimus on the luminal and abluminal surfaces); and Group V (ten stents with bioabsorbable polymer and sirolimus only on the abluminal surface). RESULTS: The following results were observed for Groups I, II, III, IV and V, respectively: percentage stenosis of 29 ± 20; 36 ± 14; 33 ± 19; 22 ± 13 and 26 ± 15 (p = 0.443); late lumen loss (in mm) of 1.02 ± 0.60; 1.24 ± 0.48; 1.11 ± 0.54; 0.72 ± 0.44 and 0.78 ± 0.39 (p = 0.253); neointimal area (in mm(2)) of 2.60 ± 1.99; 2.74 ± 1.51; 2.74 ± 1.30; 1.30 ± 1.14 and 0.97 ± 0.84 (p = 0.001; Groups IV and V versus Groups I, II and III); and percentage neointimal area of 35 ± 25; 38 ± 18; 39 ± 19; 19 ± 18 and 15 ± 12 (p = 0.001; Groups IV and V versus Groups I, II and III). Injury and inflammation scores were low and with no differences between the groups. CONCLUSION: The Inspiron(TM) stent proved to be safe and was able to significantly inhibit the neointimal hyperplasia observed on day 28 after implantation in porcine coronary arteries.